Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Reports Third Quarter 2026 Financial Results and Share Buyback Program

Mixed Impact 3 of 5 earnings

Krystal Biotech reported third quarter 2026 net product revenue of $127.3 million for VYJUVEK and net income of $63.1 million, compared to $79.4 million in the prior year period. The company also announced that its board of directors authorized a share repurchase program of up to $400 million.

Key points

  • Third quarter 2026 net product revenue for VYJUVEK was $127.3 million, up 30% year-over-year.
  • Net income for the third quarter of 2026 was $63.1 million, or $2.05 per diluted share.
  • Cash, cash equivalents, and investments totaled $1.2 billion as of September 30, 2026.
  • The board authorized a share repurchase program of up to $400 million.

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECNov 2, 2026, 7:07 AM ET
Accession number0001711279-26-000072

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 2, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.